カテゴリ： GlobalData, カナダ, 企業調査

Concordia International Corp (CXR)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Concordia International Corp (CXR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014255
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：97
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：カナダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products comprise Orapred, Donnatal, Ulesfia, Zonegran, Dibenzyline, Dutoprol, Dyrenium, Fortaz, Kayexalate, Lanoxin, Parnate, Nilandron, and Uroxatral. Concordia offers products in the forms of injectables, tablets, capsules and powders. Its target treatment areas comprise endobronchial cancer, esophageal cancer, high grade dysplasia in Barrett’s esophagus, asthma and head lice infestation among others. The company operates in Oakville, Bridgetown, Lenexa, Bannockburn, and Charlottesville. Concordia is headquartered in Oakville, Ontario, Canada.

Concordia International Corp (CXR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Concordia International Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Concordia International Corp, Medical Devices Deals, 2011 to YTD 2017 10
Concordia International Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Concordia International Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Concordia Healthcare Acquires Four Generic Products for USD41 Million 13
Concordia Healthcare Acquires Assets from Covis Pharma for USD1.2 Billion 14
Concordia Healthcare Completes Acquisition Of Donnatal From Revive Pharma For USD265.3 Million 16
Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 18
Pinnacle Biologics Acquires PHOTOFRIN And PHOTOBARR From Axcan Pharma 19
Venture Financing 21
Pinnacle Biologics Raises Funds Through Venture Financing 21
Pinnacle Biologics Secures US$1.5 Million In Venture Financing 22
Private Equity 23
Concordia International May Sell its Minority Stake 23
Cinven Acquires Mercury Pharma from HgCapital for USD730 Million 24
Partnerships 26
Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 26
Pinnacle Biologics Enters into Distribution Agreement with Orphan Canada for Photofrin 27
Concordia Healthcare Enters Into Distribution Agreement With Lachlan Pharma For Ulesfia Lotion 28
Pinnacle Biologics Enters Into Co-Marketing Agreement With Alkopharma 29
Licensing Agreements 30
Pinnacle Oncology Enters Into Licensing Agreement With University Of Chicago For Radioprotector Technology 30
Equity Offering 31
Concordia Healthcare Raises USD520 Million in Public Offering of Shares 31
Concordia Healthcare Raises USD288 Million in Public Offering of Subscription Receipts 33
Concordia Healthcare Completes Public Offering Of Shares For US$61 Million 34
Concordia Healthcare Announces Private Placement Of Securities For US$29 Million 35
Debt Offering 36
Concordia Raises USD266 Million in Public Offering of 9% Notes Due 2022 36
Concordia Healthcare Raises USD790 Million in Private Placement of 9.5% Notes Due 2022 37
Concordia Healthcare Raises USD735 Million in Private Placement of 7% Notes Due 2023 38
Acquisition 39
Concordia Healthcare Acquires Amdipharm Mercury for USD3.54 Billion 39
Amdipharm Mercury Acquires Boucher and Muir 41
Amdipharm Mercury acquires Primegen 42
Mercury Pharma Acquires Focus Pharma 43
Concordia Healthcare Acquires Pinnacle Biologics 44
Amdipharm Mercury Acquires Abcur, Specialty Pharma Company 46
Mercari Acquisition To Acquire Concordia Healthcare In Reverse Takeover Transaction 47
Concordia International Corp – Key Competitors 49
Concordia International Corp – Key Employees 50
Concordia International Corp – Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Recent Developments 52
Strategy And Business Planning 52
Sep 06, 2017: Concordia International Announces DELIVER Strategy 52
Financial Announcements 53
Nov 14, 2017: Concordia International Announces Third Quarter 2017 Results 53
Aug 11, 2017: Concordia International Announces Second Quarter 2017 Results 57
May 10, 2017: Concordia International Announces First Quarter 2017 Results 61
Mar 15, 2017: Concordia International Announces Fourth Quarter and Fiscal 2016 Results 64
Nov 07, 2016: Concordia International Announces Third Quarter 2016 Results 66
Aug 12, 2016: Concordia International Announces Second Quarter 2016 Results 69
May 13, 2016: Concordia Healthcare Announces First Quarter 2016 Results and Acquisition of Four Products with Global Rights 72
Mar 23, 2016: Concordia Healthcare Announces Fourth Quarter And Fiscal 2015 Results 75
Corporate Communications 78
May 04, 2017: Concordia International Announces Two New Appointments to the Board of Directors 78
Apr 26, 2017: Concordia International Appoints David Price as Chief Financial Officer 79
Jan 04, 2017: RedHill and Concordia sign co-promotion agreement for Donnatal drug promotion 80
Nov 02, 2016: Concordia International announces new leadership appointments 81
Oct 21, 2016: Concordia International Announces CEO Transition Plan 82
Oct 13, 2016: Concordia International Appoints Allan Oberman to Board of Directors 83
Mar 23, 2016: Concordia Healthcare Announces Board Appointment 84
Legal and Regulatory 85
Oct 11, 2017: Concordia International Announces New Communication With CMA 85
Mar 06, 2017: Concordia International Grant of Treble Damages Further Vindicates Marketing Rights of its Donnatal Brand 86
Oct 25, 2016: Concordia International Announces Communication With CMA 87
Government and Public Interest 88
May 31, 2017: Concordia International Announces Results of First CMA Stop/Go Decision 88
Product News 89
06/17/2016: Concordia Healthcare Announces PDT With Photofrin Data And Provides Corporate Update 89
Product Approvals 90
Jun 30, 2016: Concordia International Announces FDA Approval for New Photofrin Laser 90
Other Significant Developments 91
Jun 21, 2017: Concordia International Provides Update on Development of Long-Term Growth Strategy 91
Dec 19, 2016: Concordia International Provides Business Update 92
Aug 03, 2016: Concordia International Confirms That Strategic Review is Ongoing and Provides Update on its Business 93
Jul 13, 2016: Concordia International Provides Additional Disclosure in Relation to Brexit’s Impact on its Business 94
Jun 28, 2016: Concordia Healthcare Announces Name Change To Concordia International And Comments On Brexit’s Impact On The Company’s Business 95
Jan 11, 2016: Concordia Healthcare Provides Corporate Update 96
Appendix 97
Methodology 97
About GlobalData 97
Contact Us 97
Disclaimer 97

List of Tables
Concordia International Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Concordia International Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Concordia International Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Concordia International Corp, Medical Devices Deals, 2011 to YTD 2017 10
Concordia International Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Concordia Healthcare Acquires Four Generic Products for USD41 Million 13
Concordia Healthcare Acquires Assets from Covis Pharma for USD1.2 Billion 14
Concordia Healthcare Completes Acquisition Of Donnatal From Revive Pharma For USD265.3 Million 16
Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 18
Pinnacle Biologics Acquires PHOTOFRIN And PHOTOBARR From Axcan Pharma 19
Pinnacle Biologics Raises Funds Through Venture Financing 21
Pinnacle Biologics Secures US$1.5 Million In Venture Financing 22
Concordia International May Sell its Minority Stake 23
Cinven Acquires Mercury Pharma from HgCapital for USD730 Million 24
Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 26
Pinnacle Biologics Enters into Distribution Agreement with Orphan Canada for Photofrin 27
Concordia Healthcare Enters Into Distribution Agreement With Lachlan Pharma For Ulesfia Lotion 28
Pinnacle Biologics Enters Into Co-Marketing Agreement With Alkopharma 29
Pinnacle Oncology Enters Into Licensing Agreement With University Of Chicago For Radioprotector Technology 30
Concordia Healthcare Raises USD520 Million in Public Offering of Shares 31
Concordia Healthcare Raises USD288 Million in Public Offering of Subscription Receipts 33
Concordia Healthcare Completes Public Offering Of Shares For US$61 Million 34
Concordia Healthcare Announces Private Placement Of Securities For US$29 Million 35
Concordia Raises USD266 Million in Public Offering of 9% Notes Due 2022 36
Concordia Healthcare Raises USD790 Million in Private Placement of 9.5% Notes Due 2022 37
Concordia Healthcare Raises USD735 Million in Private Placement of 7% Notes Due 2023 38
Concordia Healthcare Acquires Amdipharm Mercury for USD3.54 Billion 39
Amdipharm Mercury Acquires Boucher and Muir 41
Amdipharm Mercury acquires Primegen 42
Mercury Pharma Acquires Focus Pharma 43
Concordia Healthcare Acquires Pinnacle Biologics 44
Amdipharm Mercury Acquires Abcur, Specialty Pharma Company 46
Mercari Acquisition To Acquire Concordia Healthcare In Reverse Takeover Transaction 47
Concordia International Corp, Key Competitors 49
Concordia International Corp, Key Employees 50
Concordia International Corp, Subsidiaries 51

★海外企業調査レポート[Concordia International Corp (CXR)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Fujifilm Corp：企業の戦略的SWOT分析
    Fujifilm Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Enterprise Products Partners L.P.：企業の戦略・SWOT・財務情報
    Enterprise Products Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Enterprise Products Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • CFM International, Inc.：企業の戦略・SWOT・財務情報
    CFM International, Inc. - Strategy, SWOT and Corporate Finance Report Summary CFM International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Obuv Rossii OOO (OBUV)：企業の財務・戦略的SWOT分析
    Obuv Rossii OOO (OBUV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Aselsan Elektronik Sanayi Ve Ticaret A.S.：企業の戦略・SWOT・財務分析
    Aselsan Elektronik Sanayi Ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report Summary Aselsan Elektronik Sanayi Ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Strukton Groep Nv：企業の戦略・SWOT・財務分析
    Strukton Groep Nv - Strategy, SWOT and Corporate Finance Report Summary Strukton Groep Nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Traverse Biosciences Inc-製薬・医療分野：企業M&A・提携分析
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an independent bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company’s lead candidate TRB-N0224 is developed for canin …
  • Robert Walters Plc (RWA)：企業の財務・戦略的SWOT分析
    Summary Robert Walters Plc (Robert Walters) is a recruitment and consultancy service provider. The company offers placements of professionals on permanent, contract and interim positions. It offers recruitment services for accountancy and finance, banking and financial services, executive search, pr …
  • Jumeirah Group：企業の戦略・SWOT・財務分析
    Jumeirah Group - Strategy, SWOT and Corporate Finance Report Summary Jumeirah Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Walker Greenbank PLC：企業の戦略・SWOT・財務情報
    Walker Greenbank PLC - Strategy, SWOT and Corporate Finance Report Summary Walker Greenbank PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Corvidia Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Corvidia Therapeutics Inc (Corvidia Therapeutics) is a clinical stage biotechnology company that develops cardiovascular and cardio-renal therapies leveraging functional genomics. The company develops COR-001 for the treatment of chronic kidney disease on dialysis (under phase 2 stage), and …
  • Ono Pharmaceutical Co Ltd (4528)：企業の財務・戦略的SWOT分析
    Ono Pharmaceutical Co Ltd (4528) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Hornbeck Offshore Services Inc (HOS)：企業の財務・戦略的SWOT分析
    Hornbeck Offshore Services Inc (HOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Omega Pharma NV：企業の戦略・SWOT・財務情報
    Omega Pharma NV - Strategy, SWOT and Corporate Finance Report Summary Omega Pharma NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • The Rank Group Plc (RNK)：企業の財務・戦略的SWOT分析
    The Rank Group Plc (RNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Odakyu Electric Railway Co., Ltd. (9007)：企業の財務・戦略的SWOT分析
    Odakyu Electric Railway Co., Ltd. (9007) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comp …
  • ALPCO Diagnostics：医療機器：M&Aディール及び事業提携情報
    Summary ALPCO Diagnostics (ALPCO) is a life science company that imports and distributes immunoassay based products. The company offers immunoassays, chemiluminescent assays, flow cytometry reagents, purified antibodies, recombinant proteins, and HPLC and MS-MS reagents. It provides food additives, …
  • Aohata Corporation：企業の戦略・SWOT・財務情報
    Aohata Corporation - Strategy, SWOT and Corporate Finance Report Summary Aohata Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Galp Energia SGPS SA (GALP)：電力：M&Aディール及び事業提携情報
    Summary Galp Energia SGPS SA (Galp) is an integrated energy company. It explores for, develops and produces crude oil and natural gas, refines crude oil, and markets refined petroleum products. The company also conducts power generation, produces biodiesel and trades gas. It imports, transports and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆